Please assess the completion status of the following clinical trial:

Trial Title: Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Immunocompromised due to hematologic malignancies, bone marrow failure syndromes, hematopoietic stem cell transplantation, solid organ transplantation, other conditions resulting in severe neutropenia, HIV infection, prolonged corticosteroid therapy, treatment with other immunosuppressive medications, or other immunocompromising conditions that place patients at risk for invasive fungal infections.~* Evidence of proven or probable invasive aspergillosis, by modified EORTC criteria~Exclusion Criteria:~* Concomitant other systemic antifungal agents are not permitted on study.~* Chronic invasive fungal infection, defined as signs/symptoms of invasive fungal infection present for \> 4 weeks preceding entry into study~* Prior systemic therapy of ≥ 4 days with any polyene anti-fungal agent within 14 days of study enrollment~* Prior systemic therapy of ≥ 4 days with non-polyenes for the current, documented IFI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1st cohort (Type: EXPERIMENTAL): 70mg caspofungin 1x/day
- 2nd cohort (Type: EXPERIMENTAL): 100mg caspofungin 1x/day
- 3rd cohort (Type: EXPERIMENTAL): 150mg caspofungin 1x/day
- 4th cohort (Type: EXPERIMENTAL): 200mg caspofungin 1x/day

Based on this trial design, predict the completion outcome and termination type (if applicable).